{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"Synonym","name":"CDK2 kinase inhibitor INCB123667"},{"type":"CodeName","name":"INCB 123667"},{"type":"CodeName","name":"INCB-123667"},{"type":"CodeName","name":"INCB123667"}],"definition":{"html":"An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon oral administration, CDK2 inhibitor INCB123667 selectively targets, binds to and inhibits the activity of CDK2. This inhibits retinoblastoma (Rb) phosphorylation and blocks G1/S transition, which leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDK2, in complex with cyclin E1 (CCNE1; CCNE-1), phosphorylates Rb, which leads to E2F target gene expression and G1 to S-phase cell cycle progression. CDK2 and CCNE1 are overexpressed in various tumor cell types.","text":"An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), with potential antineoplastic activity. Upon oral administration, CDK2 inhibitor INCB123667 selectively targets, binds to and inhibits the activity of CDK2. This inhibits retinoblastoma (Rb) phosphorylation and blocks G1/S transition, which leads to cell cycle arrest, the induction of apoptosis, and the inhibition of tumor cell proliferation. CDK2, in complex with cyclin E1 (CCNE1; CCNE-1), phosphorylates Rb, which leads to E2F target gene expression and G1 to S-phase cell cycle progression. CDK2 and CCNE1 are overexpressed in various tumor cell types."},"drugInfoSummaryLink":null,"nciConceptId":"C212984","nciConceptName":"CDK2 Inhibitor INCB123667","termId":818065,"name":"CDK2 inhibitor INCB123667","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cdk2-inhibitor-incb123667"}],"links":null}